FDA Rejects Replimune’s Engineered Virus for Melanoma Again, Sparking Regulatory Debate
TL;DR
The FDA has once more rejected Replimune’s engineered virus therapy for advanced melanoma, a decision that underscores the ongoing debate over tightening agency standards amid leadership changes; the treatment is designed to boost the immune system’s attack on skin cancer, but regulators say the data remain insufficient.
Topics:businessbiotechnology#biotechnology#fda#melanoma#regulatory-standards#replimune#virus-based-therapy
- Replimune skin cancer drug that became FDA flashpoint is rejected again statnews.com
- FDA again spurns Replimune melanoma drug BioPharma Dive
- Replimune lead drug rejected by FDA again (REPL:NASDAQ) Seeking Alpha
- US FDA declines to approve Replimune's drug for advanced skin cancer Yahoo
- Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
Want the full story? Read the original reporting
Read on statnews.com